Boost for GSK as new bone marrow most cancers drug drastically cuts threat of dying in sufferers
A cancer drug developed by GSK drastically cuts the risk of death in patients, trials have shown.
The pharma giant’s Blenrep treatment was shown in a recent study to have reduced the risk of death by 42 per cent in those suffering from multiple myeloma, a type of bone marrow cancer.
While the disease is still incurable, the data showed patients taking Blenrep would survive nearly three years longer than those using existing treatments.
The results are a boost for GSK and boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.
Blenrep could be worth more than £3billion in annual sales for GSK if it comes to market.
The drug has been accepted for priority review by Chinese regulators after a similar move last month by US watchdogs.
Trial success: GSK boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines
DIY INVESTING PLATFORMS
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
